157 related articles for article (PubMed ID: 37608029)
21. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
Yoshizato T; Nannya Y; Imai Y; Ichikawa M; Kurokawa M
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):410-6. PubMed ID: 23747081
[TBL] [Abstract][Full Text] [Related]
23. Predictive impact of soluble interleukin-2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B-cell lymphoma.
Shichijo T; Tatetsu H; Nosaka K; Higuchi Y; Kikukawa Y; Inoue Y; Toyoda K; Yasunaga JI; Matsuoka M
EJHaem; 2022 May; 3(2):385-393. PubMed ID: 35846027
[TBL] [Abstract][Full Text] [Related]
24. Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma.
Toji T; Takata K; Sato Y; Miyata-Takata T; Hayashi E; Habara T; Maeda Y; Tanimoto M; Yoshino T
J Clin Pathol; 2015 Aug; 68(8):622-7. PubMed ID: 25935549
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
27. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
Ansell SM; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Witzig TE; Macon WR; Dogan A; Cerhan JR; Novak AJ
Am J Hematol; 2012 Sep; 87(9):865-9. PubMed ID: 22674570
[TBL] [Abstract][Full Text] [Related]
28. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
29. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
[TBL] [Abstract][Full Text] [Related]
32. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
[TBL] [Abstract][Full Text] [Related]
33. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Umino K; Fujiwara SI; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Lymphoma; 2017 Feb; 58(2):316-323. PubMed ID: 27267694
[TBL] [Abstract][Full Text] [Related]
34. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein.
Izzo F; Cremona F; Delrio P; Leonardi E; Castello G; Pignata S; Daniele B; Curley SA
Ann Surg Oncol; 1999 Mar; 6(2):178-85. PubMed ID: 10082044
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS
Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584
[TBL] [Abstract][Full Text] [Related]
36. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.
Kamihira S; Atogami S; Sohda H; Momita S; Yamada Y; Tomonaga M
Cancer; 1994 Jun; 73(11):2753-8. PubMed ID: 8194016
[TBL] [Abstract][Full Text] [Related]
37. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
38. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
39. Relationship between levels of serum gastric inhibitory polypeptide (GIP), soluble interleukin-2 receptor (sIL-2R), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and disease condition and prognosis of patients with severe acute pancreatitis.
Zeng L; Xi F; Yang Y; Guo L; Hu H; Yang Q; Ma Q
Ann Palliat Med; 2021 Jun; 10(6):6786-6792. PubMed ID: 34154356
[TBL] [Abstract][Full Text] [Related]
40. [Expression of SIL-2R in Patients with Multiple Myeloma and Its Clinical Significance].
Lin P; Lin XR; Liu QL; Zhang XY; Chen GW; Xie RT; Zhang YL; DU XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1797-1802. PubMed ID: 36476906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
